Filing Flows

Filing Flows › UroGen Pharma (URGN) › Next earnings date

UroGen Pharma (URGN) earnings: missed the estimate

UroGen Pharma (URGN) reported on Nov 4, 2026 and missed the EPS estimate: −$0.03 against $0.10 (-131.0%). Revenue was $89.0M for Q3 2026, +224% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−131.0% vs estimate
Beat rate20%

The last report

UroGen Pharma reported revenue of $89.0M for the third quarter 2026 (+224% Y/Y), net loss $1.5M: Zusduri $68.0M, Jelmyto $21.0M. How it makes money → · Every quarter →

UroGen Pharma: EPS against the estimate, last 5 reportsUroGen Pharma: EPS against the estimate, last 5 reportsEstimateReported−$0.68−$0.69Nov 25−$0.51−$0.53Mar 26−$0.48−$0.47May 26−$0.27−$0.28Aug 26$0.10−$0.03Nov 26
Latest (Nov 26): Estimate $0.10, Reported −$0.03.

UroGen Pharma's latest quarter

UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did UroGen Pharma beat earnings?

UroGen Pharma (URGN) reported on Nov 4, 2026 and missed the EPS estimate: −$0.03 against $0.10 (-131.0%).

When does URGN report earnings?

The next date is not set yet.

Does UroGen Pharma usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.